Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
NCT ID: NCT07091526
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
168 participants
OBSERVATIONAL
2025-07-29
2026-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High serum uric acid
The increase of after serum uric acid operation compared with that before operation is≥10% Normal levels serum uric acid are typically 178 to 360 μm (3 to 6.8 mg/dl).
serum uric acid test
Detect the serum uric acid in blood sample
Low serum uric acid
The increase of after serum uric acid operation compared with that before operation \< 10% Normal serum uric acid levels are typically 178 to 360 μm (3 to 6.8 mg/dl).
serum uric acid test
Detect the serum uric acid in blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum uric acid test
Detect the serum uric acid in blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
* The postoperative survival time was at least 6 weeks
Exclusion Criteria
* Patients who underwent emergency hemodialysis or plasma exchange after surgery
* History of gout or long-term urate-lowering therapy, such as allopurinol
* Patients are missing follow-up data
* Hydrochlorothiazide and furosemide were used
* Chronic kidney disease
* Oncolytic syndrome
* Hemolytic anemia
* Lead poisoning
* Hyperparathyroidism
* Hypothyroidism
* A tyrosinase inhibitor was used
* Patients with nonpancreatic primary tumors
* Pregnant or postpartum women.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hepatopancreatobiliary Surgery Institute of Gansu Province
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wenbo Meng
Director of Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wenbo Meng, M.D. Ph. D.
Role: PRINCIPAL_INVESTIGATOR
Hepatopancreatobiliary Surgery Institute of Gansu Province
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hepatopancreatobiliary Surgery Institute of Gansu Province
Lanzhou, Gansu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wenbo Meng, MD,PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061.
Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUA-PC
Identifier Type: -
Identifier Source: org_study_id